Mosepele Mosepele, M.B.,B.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Botswana | 42 | 2024 | 1040 | 2.610 |
Why?
|
HIV Infections | 47 | 2024 | 17165 | 2.270 |
Why?
|
Meningitis, Cryptococcal | 9 | 2024 | 66 | 1.570 |
Why?
|
Albuminuria | 1 | 2024 | 659 | 0.710 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 2 | 2018 | 282 | 0.660 |
Why?
|
Anti-HIV Agents | 11 | 2023 | 4491 | 0.640 |
Why?
|
Benzoxazines | 5 | 2019 | 309 | 0.610 |
Why?
|
Amphotericin B | 4 | 2022 | 142 | 0.560 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2024 | 936 | 0.530 |
Why?
|
Medication Adherence | 3 | 2023 | 2165 | 0.480 |
Why?
|
Caregivers | 2 | 2023 | 2224 | 0.460 |
Why?
|
Cephalosporins | 3 | 2023 | 204 | 0.460 |
Why?
|
HIV | 4 | 2023 | 1579 | 0.450 |
Why?
|
Hypertension | 2 | 2024 | 8594 | 0.450 |
Why?
|
Antifungal Agents | 5 | 2023 | 749 | 0.440 |
Why?
|
Cardiovascular Diseases | 4 | 2024 | 15757 | 0.440 |
Why?
|
Bartonella Infections | 1 | 2011 | 21 | 0.400 |
Why?
|
Developing Countries | 2 | 2022 | 2868 | 0.400 |
Why?
|
Cell Adhesion Molecules | 1 | 2018 | 1602 | 0.390 |
Why?
|
Receptors, Cell Surface | 2 | 2018 | 2825 | 0.380 |
Why?
|
Cryptococcus neoformans | 2 | 2024 | 121 | 0.370 |
Why?
|
Carotid Artery Diseases | 1 | 2017 | 883 | 0.360 |
Why?
|
Viral Load | 6 | 2024 | 3322 | 0.360 |
Why?
|
Antigens, CD | 2 | 2018 | 4000 | 0.350 |
Why?
|
Inflammation Mediators | 1 | 2018 | 1881 | 0.330 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2018 | 2197 | 0.330 |
Why?
|
Flucytosine | 3 | 2023 | 33 | 0.300 |
Why?
|
Africa South of the Sahara | 6 | 2022 | 742 | 0.290 |
Why?
|
Fluconazole | 3 | 2023 | 155 | 0.280 |
Why?
|
Anti-Retroviral Agents | 3 | 2021 | 1779 | 0.260 |
Why?
|
Endothelium, Vascular | 1 | 2018 | 4433 | 0.260 |
Why?
|
CD4 Lymphocyte Count | 5 | 2020 | 2569 | 0.250 |
Why?
|
Cross-Sectional Studies | 13 | 2024 | 25942 | 0.250 |
Why?
|
Prevalence | 7 | 2024 | 15687 | 0.250 |
Why?
|
Hepatitis Delta Virus | 1 | 2024 | 24 | 0.240 |
Why?
|
Hepatitis D | 1 | 2024 | 23 | 0.240 |
Why?
|
Maternal Mortality | 2 | 2024 | 300 | 0.240 |
Why?
|
Pharmacology | 1 | 2004 | 99 | 0.240 |
Why?
|
Atherosclerosis | 2 | 2017 | 3517 | 0.230 |
Why?
|
Gammaproteobacteria | 1 | 2023 | 28 | 0.230 |
Why?
|
Adult | 32 | 2024 | 219994 | 0.230 |
Why?
|
Wolves | 1 | 2023 | 10 | 0.220 |
Why?
|
Cryptococcosis | 1 | 2024 | 104 | 0.220 |
Why?
|
Pilot Projects | 7 | 2023 | 8555 | 0.200 |
Why?
|
Dog Diseases | 1 | 2023 | 141 | 0.200 |
Why?
|
Humans | 61 | 2024 | 760621 | 0.200 |
Why?
|
Phylogeny | 3 | 2024 | 2775 | 0.200 |
Why?
|
Pregnancy Complications, Infectious | 2 | 2024 | 2125 | 0.190 |
Why?
|
Multicenter Studies as Topic | 2 | 2024 | 1722 | 0.190 |
Why?
|
Male | 33 | 2024 | 359744 | 0.190 |
Why?
|
AIDS-Related Opportunistic Infections | 2 | 2022 | 662 | 0.190 |
Why?
|
Genotype | 6 | 2024 | 12960 | 0.190 |
Why?
|
Antiretroviral Therapy, Highly Active | 4 | 2020 | 1894 | 0.190 |
Why?
|
Problem-Based Learning | 1 | 2004 | 352 | 0.180 |
Why?
|
E-Selectin | 2 | 2023 | 576 | 0.180 |
Why?
|
Enterobacteriaceae Infections | 1 | 2022 | 192 | 0.180 |
Why?
|
Female | 36 | 2024 | 391270 | 0.170 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 2 | 2023 | 691 | 0.170 |
Why?
|
Stillbirth | 4 | 2024 | 368 | 0.170 |
Why?
|
Self Efficacy | 1 | 2023 | 630 | 0.170 |
Why?
|
Pregnancy Outcome | 4 | 2024 | 2907 | 0.160 |
Why?
|
Health Occupations | 1 | 2020 | 222 | 0.160 |
Why?
|
Alkynes | 5 | 2019 | 313 | 0.160 |
Why?
|
Reverse Transcriptase Inhibitors | 2 | 2019 | 618 | 0.160 |
Why?
|
Risk Factors | 8 | 2024 | 74359 | 0.160 |
Why?
|
HIV-1 | 4 | 2022 | 6849 | 0.160 |
Why?
|
Intercellular Adhesion Molecule-1 | 2 | 2023 | 1126 | 0.160 |
Why?
|
Quarantine | 1 | 2020 | 176 | 0.160 |
Why?
|
HIV Seropositivity | 2 | 2022 | 955 | 0.160 |
Why?
|
Drug Resistance, Multiple, Viral | 1 | 2018 | 53 | 0.160 |
Why?
|
Middle Aged | 22 | 2024 | 220352 | 0.160 |
Why?
|
Cyclopropanes | 5 | 2019 | 431 | 0.150 |
Why?
|
Immune Evasion | 1 | 2022 | 362 | 0.150 |
Why?
|
Young Adult | 13 | 2024 | 58741 | 0.140 |
Why?
|
Research Personnel | 1 | 2021 | 582 | 0.130 |
Why?
|
Tuberculosis | 2 | 2023 | 2001 | 0.130 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 2018 | 412 | 0.130 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2018 | 279 | 0.130 |
Why?
|
Education, Medical, Undergraduate | 1 | 2004 | 1066 | 0.120 |
Why?
|
Quinolines | 1 | 2020 | 759 | 0.120 |
Why?
|
Antihypertensive Agents | 1 | 2024 | 2061 | 0.120 |
Why?
|
Vascular Diseases | 1 | 2023 | 1182 | 0.120 |
Why?
|
Case-Control Studies | 5 | 2018 | 22053 | 0.110 |
Why?
|
Monobactams | 2 | 2023 | 16 | 0.110 |
Why?
|
Drug Costs | 2 | 2019 | 1185 | 0.110 |
Why?
|
Motivation | 1 | 2023 | 1993 | 0.110 |
Why?
|
Sexual Partners | 1 | 2018 | 753 | 0.110 |
Why?
|
Premature Birth | 2 | 2022 | 1771 | 0.110 |
Why?
|
Personal Satisfaction | 1 | 2017 | 643 | 0.110 |
Why?
|
Comorbidity | 4 | 2021 | 10551 | 0.110 |
Why?
|
Social Class | 1 | 2021 | 2005 | 0.100 |
Why?
|
Bartonella quintana | 1 | 2011 | 3 | 0.100 |
Why?
|
Trench Fever | 1 | 2011 | 2 | 0.100 |
Why?
|
Self Report | 1 | 2024 | 3711 | 0.100 |
Why?
|
Malawi | 2 | 2024 | 301 | 0.100 |
Why?
|
Bartonella | 1 | 2011 | 11 | 0.100 |
Why?
|
Bartonella henselae | 1 | 2011 | 15 | 0.100 |
Why?
|
American Heart Association | 1 | 2017 | 1081 | 0.100 |
Why?
|
Cat-Scratch Disease | 1 | 2011 | 23 | 0.100 |
Why?
|
Glomerular Filtration Rate | 1 | 2020 | 2180 | 0.100 |
Why?
|
Patients | 1 | 2018 | 906 | 0.100 |
Why?
|
Social Support | 1 | 2021 | 2145 | 0.100 |
Why?
|
Program Development | 1 | 2017 | 1297 | 0.100 |
Why?
|
Attitude to Health | 1 | 2020 | 2029 | 0.090 |
Why?
|
Curriculum | 2 | 2020 | 3718 | 0.090 |
Why?
|
Central Nervous System | 1 | 2018 | 1334 | 0.090 |
Why?
|
Feasibility Studies | 1 | 2021 | 5201 | 0.090 |
Why?
|
Emergency Medical Services | 1 | 2022 | 1925 | 0.090 |
Why?
|
Treatment Outcome | 7 | 2024 | 65017 | 0.090 |
Why?
|
Drug Resistance, Microbial | 2 | 2023 | 856 | 0.080 |
Why?
|
Heart Diseases | 1 | 2022 | 2809 | 0.080 |
Why?
|
Mutation, Missense | 1 | 2018 | 2566 | 0.080 |
Why?
|
Pregnancy Complications | 1 | 2022 | 2942 | 0.080 |
Why?
|
Oxidoreductases, N-Demethylating | 1 | 2008 | 110 | 0.080 |
Why?
|
Interleukin-6 | 1 | 2018 | 3215 | 0.080 |
Why?
|
Mental Disorders | 2 | 2022 | 6796 | 0.080 |
Why?
|
Monocytes | 1 | 2017 | 2575 | 0.070 |
Why?
|
Cost-Benefit Analysis | 4 | 2022 | 5508 | 0.070 |
Why?
|
Blood Pressure | 1 | 2023 | 8525 | 0.070 |
Why?
|
Primary Health Care | 1 | 2024 | 4647 | 0.070 |
Why?
|
Drug Administration Schedule | 3 | 2022 | 4899 | 0.070 |
Why?
|
Anti-Bacterial Agents | 2 | 2023 | 7408 | 0.070 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2008 | 253 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2024 | 10344 | 0.070 |
Why?
|
South Africa | 2 | 2023 | 1821 | 0.070 |
Why?
|
Electronic Health Records | 1 | 2024 | 4775 | 0.070 |
Why?
|
Drug Therapy, Combination | 3 | 2023 | 6498 | 0.070 |
Why?
|
Health Expenditures | 1 | 2019 | 2362 | 0.070 |
Why?
|
Cognition Disorders | 2 | 2011 | 3976 | 0.070 |
Why?
|
Immunocompromised Host | 1 | 2011 | 857 | 0.070 |
Why?
|
Social Stigma | 2 | 2023 | 734 | 0.070 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2020 | 2290 | 0.070 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2016 | 2128 | 0.060 |
Why?
|
Outpatients | 2 | 2024 | 1607 | 0.060 |
Why?
|
Clinical Trials as Topic | 1 | 2021 | 8056 | 0.060 |
Why?
|
Communicable Disease Control | 2 | 2022 | 844 | 0.060 |
Why?
|
RNA, Ribosomal, 28S | 1 | 2024 | 10 | 0.060 |
Why?
|
Mass Screening | 1 | 2020 | 5423 | 0.060 |
Why?
|
Agar | 1 | 2023 | 55 | 0.060 |
Why?
|
Alcohol Drinking | 1 | 2016 | 4013 | 0.060 |
Why?
|
Chronic Disease | 1 | 2018 | 9287 | 0.050 |
Why?
|
Hydrolases | 1 | 2023 | 146 | 0.050 |
Why?
|
Vitamin D Deficiency | 1 | 2012 | 1379 | 0.050 |
Why?
|
Mutation | 2 | 2024 | 29932 | 0.050 |
Why?
|
Myocardial Infarction | 1 | 2024 | 11891 | 0.050 |
Why?
|
Hospital Mortality | 1 | 2016 | 5425 | 0.050 |
Why?
|
Time Factors | 3 | 2018 | 40165 | 0.050 |
Why?
|
Clinical Competence | 1 | 2017 | 4783 | 0.050 |
Why?
|
Adolescent | 4 | 2023 | 87810 | 0.050 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2018 | 15789 | 0.050 |
Why?
|
Depression | 2 | 2012 | 8044 | 0.050 |
Why?
|
Carbapenems | 1 | 2022 | 123 | 0.050 |
Why?
|
Hepatitis B virus | 1 | 2024 | 522 | 0.050 |
Why?
|
Pregnancy | 4 | 2024 | 29749 | 0.050 |
Why?
|
Treatment Failure | 2 | 2017 | 2648 | 0.050 |
Why?
|
Statistical Distributions | 1 | 2020 | 63 | 0.050 |
Why?
|
Australia | 1 | 2004 | 1289 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2018 | 5397 | 0.040 |
Why?
|
Stroke | 1 | 2022 | 9962 | 0.040 |
Why?
|
Standard of Care | 1 | 2023 | 552 | 0.040 |
Why?
|
Hospitals | 2 | 2023 | 3928 | 0.040 |
Why?
|
Universities | 1 | 2004 | 992 | 0.040 |
Why?
|
Hepatitis B | 1 | 2024 | 701 | 0.040 |
Why?
|
Vitamin D | 1 | 2012 | 3291 | 0.040 |
Why?
|
Personnel Loyalty | 1 | 2017 | 11 | 0.040 |
Why?
|
Dogs | 1 | 2023 | 3841 | 0.040 |
Why?
|
Authorship | 1 | 2021 | 281 | 0.040 |
Why?
|
Infant, Small for Gestational Age | 1 | 2020 | 460 | 0.040 |
Why?
|
Prospective Studies | 5 | 2023 | 54303 | 0.040 |
Why?
|
Drug Resistance, Viral | 1 | 2022 | 859 | 0.040 |
Why?
|
Internship and Residency | 1 | 2017 | 5870 | 0.040 |
Why?
|
Faculty | 1 | 2020 | 383 | 0.040 |
Why?
|
Longitudinal Studies | 2 | 2024 | 14495 | 0.040 |
Why?
|
Recombination, Genetic | 1 | 2022 | 1526 | 0.040 |
Why?
|
Health Personnel | 2 | 2020 | 3310 | 0.030 |
Why?
|
Chest Pain | 1 | 2024 | 1106 | 0.030 |
Why?
|
Teaching | 1 | 2004 | 1169 | 0.030 |
Why?
|
Alleles | 2 | 2018 | 6898 | 0.030 |
Why?
|
Hospitalization | 1 | 2016 | 10790 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2023 | 21025 | 0.030 |
Why?
|
Oxazines | 1 | 2018 | 341 | 0.030 |
Why?
|
Poverty | 2 | 2022 | 2695 | 0.030 |
Why?
|
Homosexuality, Male | 1 | 2024 | 1273 | 0.030 |
Why?
|
Cell Proliferation | 1 | 2011 | 10446 | 0.030 |
Why?
|
Cohort Studies | 4 | 2020 | 41335 | 0.030 |
Why?
|
Focus Groups | 1 | 2021 | 1378 | 0.030 |
Why?
|
Risk Assessment | 1 | 2017 | 24123 | 0.030 |
Why?
|
Birth Weight | 1 | 2023 | 2097 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2018 | 861 | 0.030 |
Why?
|
Interprofessional Relations | 1 | 2020 | 989 | 0.030 |
Why?
|
Polymerase Chain Reaction | 1 | 2024 | 6068 | 0.030 |
Why?
|
Delivery of Health Care | 2 | 2022 | 5325 | 0.030 |
Why?
|
Sexual Behavior | 1 | 2024 | 2086 | 0.030 |
Why?
|
Administration, Oral | 1 | 2022 | 4035 | 0.030 |
Why?
|
Placenta | 1 | 2023 | 1702 | 0.030 |
Why?
|
Infant, Newborn | 2 | 2024 | 26181 | 0.030 |
Why?
|
Qualitative Research | 1 | 2023 | 2963 | 0.030 |
Why?
|
Pyridones | 1 | 2018 | 792 | 0.030 |
Why?
|
Bacteria | 1 | 2024 | 2199 | 0.030 |
Why?
|
Life Style | 1 | 2024 | 3896 | 0.030 |
Why?
|
Antibodies, Neutralizing | 1 | 2022 | 1933 | 0.020 |
Why?
|
Heart Failure | 1 | 2016 | 11847 | 0.020 |
Why?
|
Activities of Daily Living | 2 | 2012 | 2417 | 0.020 |
Why?
|
Infant | 2 | 2024 | 36060 | 0.020 |
Why?
|
Models, Molecular | 1 | 2022 | 5434 | 0.020 |
Why?
|
Escherichia coli | 1 | 2023 | 4219 | 0.020 |
Why?
|
Schools, Medical | 1 | 2017 | 878 | 0.020 |
Why?
|
Psychiatric Status Rating Scales | 2 | 2012 | 6015 | 0.020 |
Why?
|
Inpatients | 1 | 2022 | 2581 | 0.020 |
Why?
|
Age Factors | 2 | 2019 | 18416 | 0.020 |
Why?
|
Counseling | 1 | 2018 | 1548 | 0.020 |
Why?
|
Cardiovascular Agents | 1 | 2016 | 867 | 0.020 |
Why?
|
AIDS Dementia Complex | 1 | 2010 | 153 | 0.020 |
Why?
|
Program Evaluation | 1 | 2017 | 2493 | 0.020 |
Why?
|
RNA, Viral | 1 | 2017 | 2838 | 0.020 |
Why?
|
United States | 1 | 2017 | 72461 | 0.020 |
Why?
|
Behavior | 1 | 2011 | 540 | 0.020 |
Why?
|
Piperazines | 1 | 2018 | 2525 | 0.020 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2016 | 1717 | 0.020 |
Why?
|
Neuropsychological Tests | 2 | 2011 | 7021 | 0.020 |
Why?
|
Task Performance and Analysis | 1 | 2011 | 759 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2019 | 10827 | 0.020 |
Why?
|
Health Behavior | 1 | 2018 | 2622 | 0.020 |
Why?
|
Odds Ratio | 1 | 2018 | 9716 | 0.020 |
Why?
|
Acute Disease | 1 | 2016 | 7269 | 0.020 |
Why?
|
Risk | 1 | 2017 | 9631 | 0.020 |
Why?
|
Survival Analysis | 1 | 2017 | 10182 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2018 | 12159 | 0.010 |
Why?
|
Child | 2 | 2023 | 79806 | 0.010 |
Why?
|
Follow-Up Studies | 2 | 2019 | 39261 | 0.010 |
Why?
|
Peptide Fragments | 1 | 2016 | 5125 | 0.010 |
Why?
|
Urban Population | 1 | 2012 | 2022 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8624 | 0.010 |
Why?
|
Ventricular Function, Left | 1 | 2016 | 3880 | 0.010 |
Why?
|
Logistic Models | 1 | 2018 | 13314 | 0.010 |
Why?
|
Cognition | 2 | 2011 | 6957 | 0.010 |
Why?
|
Length of Stay | 1 | 2016 | 6479 | 0.010 |
Why?
|
Sex Factors | 1 | 2016 | 10547 | 0.010 |
Why?
|
Haplotypes | 1 | 2008 | 2764 | 0.010 |
Why?
|
Aged | 3 | 2022 | 169152 | 0.010 |
Why?
|
Suicide | 1 | 2012 | 1599 | 0.010 |
Why?
|
Memory | 1 | 2010 | 2179 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2012 | 7806 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2022 | 58995 | 0.010 |
Why?
|
Incidence | 1 | 2011 | 21392 | 0.010 |
Why?
|
Animals | 1 | 2023 | 167963 | 0.010 |
Why?
|